Medios Individualised Therapies from Medios AG - home infusion service grows quietly in niche care

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 02:58. Details in the imprint.

Medios Individualised Therapies starts for the patient the moment a nurse rings the doorbell with a cooled infusion bag and a small portable pump humming softly on the kitchen table. The home service turns complex specialty drugs into something that fits into a normal Wednesday afternoon.

What the service offers

Medios Individualised Therapies is a bundled offering from Medios AG that combines compounding of specialty medicines with a home infusion service for patients with chronic and oncological diseases in Germany. The company focuses on tailor-made therapy, including dose-adjusted preparations for individual patients.

At the core of the service are patient-specific infusion solutions prepared in pharmacies that work within the Medios network, alongside logistics that move chilled medicines from clean rooms to living rooms within tight time windows. A registered nurse then handles cannulas, pumps and monitoring so that the therapy can be delivered safely outside the hospital.

How it changes everyday treatment

For many patients, the biggest change is the setting: the drip stand next to the couch instead of in a crowded outpatient clinic, the quiet click of the pump competing only with the sound of a streaming series, not with overhead announcements. That shift from institutional light to home light can make a long infusion block feel more like a part of daily life than a disruption.

Clinical oncologists and hematologists use the Medios network to prescribe complex therapies which are then prepared individually, rather than relying only on standard factory-filled vials. This can matter when body weight, organ function or prior treatments require dose adjustments beyond off-the-shelf pack sizes.

Faces behind individualised care

Medios AG is led by CEO Matthias Gärtner, who positions the company as a specialist partner for pharmacies and clinics rather than a classic drug manufacturer. Under his watch, the group has expanded a network of partner pharmacies and developed services that plug into oncology and other chronic-care pathways.

On the operational side, pharmacists and compounding specialists design workflows that minimise error risk when preparing cytostatics and biologics for single patients. Their work is partly hidden behind stainless-steel benches and laminar flow cabinets, yet it defines whether the home infusion later feels as routine as a scheduled appointment or as stressful as an emergency.

Strengths and practical limits

The strength of Medios Individualised Therapies lies in its focus on rare and complex conditions where off-the-shelf therapies may not fit neatly, and where patients benefit from fewer hospital visits. For someone with a long treatment plan, simply avoiding a weekly commute to a cancer centre can free up hours and energy.

There are, however, clear limits. Not every infusion is suitable for home administration, and physicians must weigh stability of the drug, the risk of acute reactions and the patient’s social environment. If a therapy requires immediate access to intensive care in case of complications, the home model becomes the wrong setting.

Where the service fits in Germany

Medios focuses on the German market, where statutory health insurers and hospitals seek to balance cost control with quality of care, particularly in oncology and rare diseases. Home infusion services only work when reimbursement structures recognise the value of shifting part of care away from hospital beds.

In practice, Medios builds its role as an intermediary: physicians prescribe, pharmacies compound, nurses administer, and the company stitches the pieces together under one organisational umbrella. That makes the service more about coordination than about a single product box on a pharmacy shelf.

Stock and company context

Medios AG has grown as a specialist provider in the German specialty pharma segment, operating without the scale of global giants but with a focused niche in individualised therapies and distribution. On 2026-06-26 Medios AG shares (ISIN DE000A1MMCC8) traded on Xetra around 18 euros, reflecting how investors currently value this niche positioning.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.